TCT-168 TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold implantation for recovery of vascular function after successful Chronic Total Occlusion recanalization

TCT-168 TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold implantation for recovery of vascular function after successful Chronic Total Occlusion recanalization

At linear mixed model, CBF exhibited significantly higher values in the Ticagrelor as compared to Clopidogrel group during multiple stepwise adenosine infusion, even after adjustment for age (p=0.029; Figure 1). Conclusion The TIGER BVS trial showed that Ticagrelor may be efficacious in improving co...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American College of Cardiology 2017-10, Vol.70 (18), p.B72-B72
Hauptverfasser: Brugaletta, Salvatore, Lara, Josep Gomez, Caballero-Borrego, Juan, Ortega-Paz, Luis, Gila, Luis Teruel, Jimenez, Miriam, Romaguera, Rafael, Martinez, Vicente Alcalde, Ñato, Marcos, Molina, Eduardo, Gomez-Hospital, Joan Antoni, Vilchez, Concepcion Correa, Cequier, Angel, Sabate, Manel
Format: Artikel
Sprache:eng
Schlagworte:
Biocompatibility
Biomedical materials
Cardiology
Implantation
Occlusion
Recovery (Medical)
Surgical implants
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:At linear mixed model, CBF exhibited significantly higher values in the Ticagrelor as compared to Clopidogrel group during multiple stepwise adenosine infusion, even after adjustment for age (p=0.029; Figure 1). Conclusion The TIGER BVS trial showed that Ticagrelor may be efficacious in improving coronary vascular flow in CTO patients as compared to Clopidogrel.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2017.09.235